SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET® (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.
